{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:59:48Z","timestamp":1794293988000,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pheochromocytomas\u00a0(PCC) and paragangliomas (PGL) are catecholamine-producing neuroendocrine tumors. According to the World Health Organization Classification 2017, all PCC\/PGL are considered to have malignant potential. There is growing evidence that PCC\/PGL represent a metabolic disease that leads to aerobic glycolysis. Cellular energy metabolism involves both transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) and succinate dehydrogenase (SDH) subtypes, but the association of these substances with PCC\/PGL is largely unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We investigated SDHB gene mutation and protein expressions for SDHB and Nrf2 in surgical specimens from 29 PCC\/PGL. We also assessed preoperative maximum standard glucose uptake (SUVmax) on [<jats:sup>18<\/jats:sup>F]fluorodeoxy-glucose positron emission tomography and mRNA levels for <jats:italic>Nrf2<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 5 PCC\/PGL with a PASS Score\u2009\u2265\u20094 or with a moderately to poorly differentiated type in the GAPP Score, 4 were metastatic and found to be <jats:italic>SDHB<\/jats:italic> mutants with homogeneous deletion of SDHB protein. <jats:italic>SDHB<\/jats:italic> mutants showed a higher expression of Nrf2 protein and a higher preoperative SUVmax than non-<jats:italic>SDHB<\/jats:italic> mutants with a PASS\u2009&lt;\u20094 or a well-differentiated GAPP type. Furthermore, protein expression of Nrf2 was positively associated with preoperative SUVmax. The <jats:italic>Nrf2<\/jats:italic> mRNA level positively correlated with malignant phenotype, higher expression for Nrf2 protein and SDHB gene mutant, but negatively correlated with expression for SDHB protein. There was also a positive correlation between <jats:italic>Nrf2<\/jats:italic> mRNA level and SUVmax.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These results suggest that activation of Nrf2 and elevated metabolism play roles in PCC\/PGL with malignant potential that have SDHB gene mutation and SDHB deficiency.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09415-5","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T01:02:39Z","timestamp":1647565359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation"],"prefix":"10.1186","volume":"22","author":[{"given":"Takao","family":"Kamai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Uematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"9415_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr, Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"9415_CR2","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","volume":"26","author":"LD Thompson","year":"2002","unstructured":"Thompson LD. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign from Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases. Am J Surg Pathol. 2002;26:551\u201366.","journal-title":"Am J Surg Pathol"},{"key":"9415_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1530\/ERC-13-0494","volume":"21","author":"N Kimura","year":"2014","unstructured":"Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M. Phaeochromocytoma Study Group in Japan. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014;21:405\u201314.","journal-title":"Endocr Relat Cancer"},{"key":"9415_CR4","doi-asserted-by":"publisher","first-page":"e0187398","DOI":"10.1371\/journal.pone.0187398","volume":"12","author":"JM Koh","year":"2017","unstructured":"Koh JM, Ahn SH, Kim H, Kim BJ, Sung TY, Kim YH, Hong SJ, Song DE, Lee SH. Validation of Pathological Grading Systems for Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma. PLoS ONE. 2017;12:e0187398.","journal-title":"PLoS ONE."},{"key":"9415_CR5","volume-title":"WHO Classification of Tumours of Endocrine System","author":"RV Lloyd","year":"2017","unstructured":"Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine System. Lyon, France: International Agency for Research on Cancer (IARC); 2017."},{"key":"9415_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/PAP.0b013e31825c6bc6","volume":"19","author":"JA Barletta","year":"2012","unstructured":"Barletta JA, Hornick JL. Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications. Adv Anat Pathol. 2012;19:193\u2013203.","journal-title":"Adv Anat Pathol"},{"key":"9415_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/PAT.0b013e3283539932","volume":"44","author":"AJ Gill","year":"2012","unstructured":"Gill AJ. Succinate dehydrogenase (SDH) and mitochondrial driven neoplasia. Pathology. 2012;44:285\u201392.","journal-title":"Pathology"},{"key":"9415_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc1013","volume":"3","author":"C Eng","year":"2003","unstructured":"Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer. 2003;3:193\u2013202.","journal-title":"Nat Rev Cancer"},{"key":"9415_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/nrc1737","volume":"5","author":"E Gottlieb","year":"2005","unstructured":"Gottlieb E, Tomlinson IP. Mitochondrial tumor suppressors: A genetic and biochemical update. Nat Rev Cancer. 2005;5:857\u201366.","journal-title":"Nat Rev Cancer"},{"key":"9415_CR10","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1210\/jc.2006-0423","volume":"91","author":"FM Brouwers","year":"2006","unstructured":"Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, Pacak K. High Frequency of SDHB Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. J Clin Endocrinol Metab. 2006;91:4505\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"9415_CR11","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1210\/jc.2007-0709","volume":"92","author":"L Amar","year":"2007","unstructured":"Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo AP, Plouin PF. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007;92:3822\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"9415_CR12","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1158\/1078-0432.CCR-16-0606","volume":"22","author":"I Jochmanova","year":"2016","unstructured":"Jochmanova I, Pacak K. Pheochromocytoma: The First Metabolic Endocrine Cancer. Clin Cancer Res. 2016;22:5001\u201311.","journal-title":"Clin Cancer Res"},{"key":"9415_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrc3648","volume":"14","author":"PL Dahia","year":"2014","unstructured":"Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108\u201319.","journal-title":"Nat Rev Cancer"},{"key":"9415_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703\u20137.","journal-title":"Cell"},{"key":"9415_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"9415_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/bjc.2011.579","volume":"106","author":"N Tunariu","year":"2012","unstructured":"Tunariu N, Kaye SB, de Souza NM. Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer. 2012;106:619\u201328.","journal-title":"Br J Cancer"},{"key":"9415_CR17","first-page":"1059","volume":"47","author":"LK Shankar","year":"2006","unstructured":"Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D. National Cancer Institute. J Nucl Med. 2006;47:1059\u201366.","journal-title":"J Nucl Med"},{"key":"9415_CR18","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","volume":"25","author":"HJ Timmers","year":"2007","unstructured":"Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, Adams KT, Solis D, Lenders JW, Pacak K. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262\u20139.","journal-title":"J Clin Oncol"},{"key":"9415_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106\u20139.","journal-title":"Nature"},{"key":"9415_CR20","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1101\/gad.225680.113","volume":"27","author":"MC Jaramillo","year":"2013","unstructured":"Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179\u201391.","journal-title":"Genes Dev"},{"key":"9415_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2012.05.016","volume":"22","author":"Y Mitsuishi","year":"2012","unstructured":"Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012;22:66\u201379.","journal-title":"Cancer Cell"},{"key":"9415_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrc3278","volume":"12","author":"MB Sporn","year":"2012","unstructured":"Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012;12:564\u201371.","journal-title":"Nat Rev Cancer"},{"key":"9415_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/cancers12020280","volume":"12","author":"Y Liu","year":"2020","unstructured":"Liu Y, Pang Y, Caisova V, Ding J, Yu D, Zhou Y, Huynh TT, Ghayee H, Pacak K, Yang C. Targeting NRF2-Governed Glutathione Synthesis for\u00a0SDHB-Mutated Pheochromocytoma and Paraganglioma. Cancers. 2020;12:280.","journal-title":"Cancers"},{"key":"9415_CR24","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1158\/0008-5472.CAN-20-2936","volume":"81","author":"J Goncalves","year":"2021","unstructured":"Goncalves J, Moog S, Morin A, Gentric G, M\u00fcller S, Morrell AP, Kluckova K, Stewart TJ, Andoniadou CL, Lussey-Lepoutre C, B\u00e9nit P, Thakker A, Vettore L, Roberts J, Rodriguez R, Mechta-Grigoriou F, Gimenez-Roqueplo AP, Letouz\u00e9 E, Tennant DA, Favier J. Loss of SDHB Promotes Dysregulated Iron Homeostasis, Oxidative Stress, and Sensitivity to Ascorbate. Cancer Res. 2021;81:3480\u201394.","journal-title":"Cancer Res"},{"key":"9415_CR25","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1186\/s12885-015-1097-0","volume":"15","author":"T Mizuno","year":"2015","unstructured":"Mizuno T, Kamai T, Abe H, Sakamoto S, Kitajima K, Nishihara D, Yuki H, Kambara T, Betsunoh H, Yashi M, Fukabori Y, Kaji Y, Yoshida K. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer. BMC Cancer. 2015;15:1097.","journal-title":"BMC Cancer"},{"key":"9415_CR26","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1111\/cas.14977","volume":"112","author":"T Kamai","year":"2021","unstructured":"Kamai T, Higashi S, Murakami S, Arai K, Namatame T, Kijima T, Abe H, Jamiyan T, Ishida K, Shirataki H, Yoshida KI. Cancer Sci. 2021;112:3375\u201387.","journal-title":"Cancer Sci"},{"key":"9415_CR27","doi-asserted-by":"publisher","first-page":"10244","DOI":"10.1038\/s41598-019-46124-9","volume":"9","author":"RT Casey","year":"2019","unstructured":"Casey RT, Ten Hoopen R, Ochoa E, Challis BG, Whitworth J, Smith PS, Martin JE, Clark GR, Rodger F, Maranian M, Allinson K, Madhu B, Roberts T, Campos L, Anstee J, Park SM, Marker A, Watts C, Bulusu VR, Giger OT, Maher ER. SDHC epi-mutation testing in gastrointestinal stromal tumours and related tumours in clinical practice. Sci Rep. 2019;9:10244.","journal-title":"Sci Rep"},{"key":"9415_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.7171\/jbt.12-2301-003","volume":"23","author":"AM Elliott","year":"2012","unstructured":"Elliott AM, Radecki J, Moghis B, Li X, Kammesheidt A. Rapid detection of the ACMG\/ACOG-recommended 23 CFTR disease-causing mutations using ion torrent semiconductor sequencing. J Biomol Tech. 2012;23:24\u201330.","journal-title":"J Biomol Tech"},{"key":"9415_CR29","doi-asserted-by":"publisher","first-page":"187265","DOI":"10.1155\/2015\/187265","volume":"2015","author":"L Xiong","year":"2015","unstructured":"Xiong L, Xie J, Song C, Liu J, Zheng J, Liu C, Zhang X, Li P, Wang F. The Activation of Nrf2 and Its Downstream Regulated Genes Mediates the Antioxidative Activities of Xueshuan Xinmaining Tablet in Human Umbilical Vein Endothelial Cells. Evid Based Complement Alternat Med. 2015;2015:187265.","journal-title":"Evid Based Complement Alternat Med"},{"key":"9415_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2015","unstructured":"Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11:101\u201311.","journal-title":"Nat Rev Endocrinol"},{"key":"9415_CR31","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41574-020-0324-1","volume":"16","author":"PLM Dahia","year":"2020","unstructured":"Dahia PLM, Toledo RA. Recognizing hypoxia in phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2020;16:191\u20132.","journal-title":"Nat Rev Endocrinol"},{"key":"9415_CR32","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/jnci\/djt201","volume":"105","author":"I Jochmanov\u00e1","year":"2013","unstructured":"Jochmanov\u00e1 I, Yang C, Zhuang Z, Pacak K, Hypoxia-Inducible Factor Signaling in Pheochromocytoma. Turning the Rudder in the Right Direction. J Natl Cancer Inst. 2013;105:1270\u201383.","journal-title":"J Natl Cancer Inst"},{"key":"9415_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","volume":"4","author":"I Jochmanova","year":"2018","unstructured":"Jochmanova I, Pacak K. Genomic Landscape of Pheochromocytoma and Paraganglioma. Trends Cancer. 2018;4:6\u20139.","journal-title":"Trends Cancer"},{"key":"9415_CR34","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/S1470-2045(09)70164-0","volume":"10","author":"FH van Nederveen","year":"2009","unstructured":"van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Rivi\u00e8re J, Dannenberg H, Petri BJ, Komminoth P, Pacak K, Hop WC, Pollard PJ, Mannelli M, Bayley JP, Perren A, Niemann S, Verhofstad AA, de Bru\u00efne AP, Maher ER, Tissier F, M\u00e9atchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van Marck E, Ferrau F, Fran\u00e7ois J, de Herder WW, Peeters MP, van Linge A, Lenders JW, Gimenez-Roqueplo AP, de Krijger RR, Dinjens WN. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: A retrospective and prospective analysis. Lancet Oncol. 2009;10:764\u201371.","journal-title":"Lancet Oncol"},{"key":"9415_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.46.120604.141046","volume":"47","author":"TW Kensler","year":"2007","unstructured":"Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the KEAP1-NRF2-ARE pathway. Ann Rev Pharmacol Toxicol. 2007;47:89\u2013116.","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"9415_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1186\/s12885-019-6347-0","volume":"19","author":"Y Yamaguchi","year":"2019","unstructured":"Yamaguchi Y, Kamai T, Higashi S, Murakami S, Arai K, Shirataki H, Yoshida KI. Nrf2 gene mutation and single nucleotide polymorphism rs6721961 of the Nrf2 promoter region in renal cell cancer. BMC Cancer. 2019;19:1137.","journal-title":"BMC Cancer"},{"key":"9415_CR37","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12885-018-4427-1","volume":"18","author":"A Nukui","year":"2018","unstructured":"Nukui A, Narimatsu T, Kambara T, Abe H, Sakamoto S, Yoshida KI, Kamai T. Clinically significant association of elevated expression of nuclear factor E2-related factor 2 expression with higher glucose uptake and progression of upper urinary tract cancer. BMC Cancer. 2018;18:493.","journal-title":"BMC Cancer"},{"key":"9415_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","volume":"38","author":"YB Chen","year":"2014","unstructured":"Chen YB, Brannon AR, Toubaji A, Dudas ME, Won HH, Al-Ahmadie HA, Fine SW, Gopalan A, Frizzell N, Voss MH, Russo P, Berger MF, Tickoo SK, Reuter VE. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am Surg Pathol. 2014;38:627\u201337.","journal-title":"Am Surg Pathol"},{"key":"9415_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.abb.2006.03.005","volume":"450","author":"NL Alderson","year":"2006","unstructured":"Alderson NL, Wang Y, Blatnik M, Frizzell N, Walla MD, Lyons TJ, Alt N, Carson JA, Nagai R, Thorpe SR, Baynes JW. S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. Arch Biochem Biophys. 2006;450:1\u20138.","journal-title":"Arch Biochem Biophys"},{"key":"9415_CR40","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","volume":"19","author":"WM Linehan","year":"2013","unstructured":"Linehan WM, Rouault TA. Molecular pathways: fumarate hydratase-deficient kidney cancer- targeting the Warburg effect in cancer. Clin Cancer Res. 2013;19:3345\u201352.","journal-title":"Clin Cancer Res"},{"key":"9415_CR41","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1158\/1078-0432.CCR-13-2993","volume":"21","author":"R Srinivasan","year":"2015","unstructured":"Srinivasan R, Ricketts CJ, Sourbier C, Linehan WM. New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. Clin Cancer Res. 2015;21:10\u20137.","journal-title":"Clin Cancer Res"},{"key":"9415_CR42","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.ccr.2011.08.024","volume":"20","author":"A Ooi","year":"2011","unstructured":"Ooi A, Wong JC, Petillo D, Roossien D, Perrier-Trudova V, Whitten D, Min BW, Tan MH, Zhang Z, Yang XJ, Zhou M, Gardie B, Molini\u00e9 V, Richard S, Tan PH, Teh BT, Furge KA. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011;20:511\u201323.","journal-title":"Cancer Cell"},{"key":"9415_CR43","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2011.09.006","volume":"20","author":"J Adam","year":"2011","unstructured":"Adam J, Hatipoglu E, O\u2019Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp GW, Wolhuter K, Stevens M, Fischer R, Carmeliet P, Maxwell PH, Pugh CW, Frizzell N, Soga T, Kessler BM, El-Bahrawy M, Ratcliffe PJ, Pollard PJ. Renal cyst formation in Fh1-deficient mice is independent of the Hif\/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011;20:524\u201337.","journal-title":"Cancer Cell"},{"key":"9415_CR44","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.185","volume":"13","author":"RA Toledo","year":"2017","unstructured":"NGS in PPGL (NGSnPPGL) Study Group, Toledo RA, Burnichon N, Cascon A, Benn DE, Bayley JP, Welander J, Tops CM, Firth H, Dwight T, Ercolino T, Mannelli M, Opocher G, Clifton-Bligh R, Gimm O, Maher ER, Robledo M, Gimenez-Roqueplo AP, Dahia PL. Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nat Rev Endocrinol. 2017;13:233\u201347.","journal-title":"Nat Rev Endocrinol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09415-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09415-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09415-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T21:04:37Z","timestamp":1666731877000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09415-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9415"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09415-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional ethics review board of Dokkyo Medical University Hospital (approval no. 24017.R-6\u20135.). Before surgery, written consent regarding the use of surgical samples and blood, as well as data publication was requested, and protection of patient privacy in future studies was guaranteed through a signed consent form approved by our institutional Committee on Human Rights in Research. Surviving patients provided written consent for analysis using the surgical samples, through a signed form approved by our institutional Committee on Human Rights in Research. All clinical samples were anonymized before analysis to guarantee protection of patient privacy. Consequently, each patient in this cohort signed the consent form approved by our institutional Committee on Human Rights in Research (approval no. 24017.R-6\u20135.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each patient signed an informed consent and subsequent publication form that was approved by our institutional Committee on Human Rights in Research. All clinical samples were anonymized before analysis to guarantee protection of patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}